MRNA Taking Profit, Watching for a add LONG after a pullback.
MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap
in the past three months. It compares well with NVAX which as a prior penny stock has more
volatility and upside potential. In general vaccine stocks are performing well as COVID RSV
and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and
the drive for an HIV vaccine.
MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and
maybe falling to the trigger line. I will take a one- third partial off my position here
and wait for a pullback with reversal to add back into the position at a lower price.
The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management
will help me keep it that way.
in the past three months. It compares well with NVAX which as a prior penny stock has more
volatility and upside potential. In general vaccine stocks are performing well as COVID RSV
and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and
the drive for an HIV vaccine.
MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and
maybe falling to the trigger line. I will take a one- third partial off my position here
and wait for a pullback with reversal to add back into the position at a lower price.
The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management
will help me keep it that way.
交易开始:
Price pulled back 9% and so I bought some shares for a long swing trade.
评论:
Rising from the pullback.
交易开始:
MRNA moving higher as is NVAX on the FDA vaccine news. Got a good price on the add.
